Haemonetics (HAE) Liabilities and Shareholders Equity (2010 - 2026)

Haemonetics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $2.4 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 2.24% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $9.8 billion (down 2.56% YoY), while the FY2026 annual figure was $2.4 billion, down 2.24% from the prior year.
• Liabilities and Shareholders Equity was $2.4 billion for Q1 2026 at Haemonetics, down from $2.5 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.5 billion in Q2 2024 to a low of $1.8 billion in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $2.2 billion across 5 years, with a median of $2.2 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 38.94% in 2022, then retreated 3.29% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.9 billion in 2022, then increased by 17.16% to $2.2 billion in 2023, then climbed by 15.04% to $2.5 billion in 2024, then decreased by 1.6% to $2.5 billion in 2025, then dropped by 3.81% to $2.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.4 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.4 billion (Q3 2025), per Business Quant data.